论文部分内容阅读
目的 探讨原发性肝癌合并门静脉癌栓不同治疗方法的疗效,为原发性肝癌合并门静脉癌栓不同治疗方法的临床治疗提供理论依据.方法 选取2013G2-2016G2在医院接受治疗的166例原发性肝癌合并门静脉癌栓患者作为此次研究对象,根据治疗方法的不同分为A、B和C三组,A组采用肝癌切除术+癌栓切除+术后肝动脉化疗栓塞进行治疗,B组采用肝癌切除术+癌栓切除进行治疗,C组采用肝动脉化疗栓塞进行治疗,采用回顾性方法对所有患者进行分析,分析三组患者的临床资料情况,分析比较三组患者中位生存期和生存率情况.结果 A组患者中位生存期为17个月,半年、1年和3年生存率分别为922%、645%和192%;B组患者中位生存期为12个月,半年、1年和3年生存率分别为582%、416%和72%;C组患者中位生存期为5个月,半年、1年和3年生存率分别为371%、158%和0;A组患者生存率明显高于B组和C组,三组之间差异显著,具有统计学意义(P<005).结论 肝切除术和门静脉取栓术治疗原发性肝癌合并门静脉癌栓效果显著,术后采用肝动脉化疗栓塞提高疗效显著,提高了患者的生存期.
Objective To investigate the curative effect of different treatment methods for primary hepatocellular carcinoma with portal vein tumor thrombus and to provide theoretical basis for clinical treatment of different primary hepatocellular carcinoma with portal vein tumor thrombus.Methods 166 cases of primary liver cancer treated in 2013G2-2016G2 hospital were selected for primary treatment Patients with hepatocellular carcinoma and portal vein tumor thrombus were divided into A, B and C groups according to the different treatment methods. A group was treated with hepatectomy + thrombus resection + transcatheter arterial chemoembolization, and group B with HCC resection and thrombectomy were performed. C group was treated with transcatheter hepatic arterial chemoembolization. All patients were analyzed retrospectively. The clinical data of the three groups were analyzed. The median survival and survival were compared among the three groups Results The median survival of patients in group A was 17 months, and the half-year, 1-year and 3-year survival rates were 922%, 645% and 192% respectively. The median survival time in group B was 12 months, The 1-year and 3-year survival rates were 582%, 416% and 72%, respectively. The median survival time in group C was 5 months, and the half-year, 1-year and 3-year survival rates were 371%, 158% and 0%, respectively Group survival rate was significantly higher than the B group and C group, between the three groups (P0.05) .Conclusion Liver resection and portal vein thrombectomy for the treatment of primary hepatocellular carcinoma with portal vein tumor thrombus have significant effect, and postoperative use of hepatic arterial chemoembolization can improve the efficacy and improve the survival of patients period.